Veracyte prices upsized IPO at $13, the low end of the range

By Renaissance Capital,

Shutterstock photo

Veracyte, which sells molecular diagnostic tests for thyroid cancer to reduce unnecessary surgeries, raised $65 million by offering 5.0 million shares at $13, the low end of the range of $13 to $15. The company originally planned to offer 4.7 million shares. Veracyte plans to list on the NASDAQ under the symbol VCYT. Veracyte initially filed confidentially on 8/13/2013. Morgan Stanley and Leerink Swann acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: VCYT

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by